AstraZeneca withdraws Iressa MAA
Executive Summary
AstraZeneca announces withdrawal of European Marketing Authorisation Application for Iressa (gefitinib) Jan. 4, following consultation with European Medicines Agency. Decision comes in wake of Iressa's failure to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer trial (1"The Pink Sheet" Jan. 3, 2005, p. 12). "The submission of a new MAA will be considered for Iressa in future, after evaluation of the full ISEL dataset," company says. FDA is expected to provide an update on the status of Iressa's subpart H licensure in January or February. The agency could use the next round of meetings of its Oncologic Drugs Advisory Committee tentatively scheduled for March 2-3 as a forum to discuss the oncologic's status...
You may also be interested in...
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.